01 February 2022, Israel: Canonic Ltd., focused on the development of medical grade cannabis products and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), announced today that it has shipped a first batch of its unique cannabis varieties to Portugal, following receiving approval to export from the Israeli Ministry of Health and Ministry of Agriculture.
As part of its preparations for the planned 2023 commercial launch in Europe, Canonic expects to enter commercial agreements with local growers and manufactures and will work to obtain required regulatory approvals. To this end, the varieties shipped are intended to be grown in semi-commercial scale for lab testing and regulatory examinations, as required by European regulation.
